Drugs / HL1113
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07568652 | Oct → Nov 2024 | hypertensive disorder, type 2 diabetes mellitus | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL1113 | “Period 2 : HL1113, once daily” NCT07568652 ↗ |
| Route | Oral | “single oral dose” NCT07568652 ↗ |